Hofbauer, Lorenz C. http://orcid.org/0000-0002-8691-8423
Bozec, Aline
Rauner, Martina
Jakob, Franz
Perner, Sven
Pantel, Klaus http://orcid.org/0000-0001-5736-2772
Article History
Accepted: 8 March 2021
First Online: 19 April 2021
Competing interests
: L.C.H. has received honoraria for clinical trials from Alexion, Amgen, Ascendis Pharma, Novartis and Shire, and as a member of advisory boards from Amgen, Kyowa Kirin International, Shire and UCB. M.R. has received honoraria as a member of advisory boards and for lectures from Amgen and Diasorin. F.J. has received unrestricted grants and support for clinical studies from Alexion, Amgen, Lilly and Novartis, and honoraria for lectures and as a member of advisory boards from Alexion, Amgen, Kyowa Kirin International and Lilly. S.P. has received honoraria as a member of advisory boards and for lectures from AstraZeneca, Bristol Myers Squibb, MetaSystems, MSD, Novartis, Roche and Ventana Medical Systems, and research funds from Boehringer Ingelheim, Bristol Myers Squibb, MSD, Roche and Ventana Medical Systems. K.P. has ongoing patent applications related to circulating tumour cells (pending EU patent application no. 18705153.7 (PCT/EP2018/054052)) and has received honoraria from Agena, Illumina, Menarini, Novartis, Roche and Sanofi, and research funding from European Federation of Pharmaceutical Industries and Associations (EFPIA) partners (Angle, Menarini and Servier) of the CANCER-ID programme of the European Union Innovative Medicines Initiative (IMI) Joint Undertaking. A.B. declares no competing interests.